Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease

Comment on: Dietary yeast reduce inflammation in central nerve system via microflora

“…This was indeed suggested for S. cerevisiae . Anti‐ S. cerevisiae autoantibodies (ASCA) are associated with Crohn's disease and can be found even before clinical onset in ~30% of patients 3. Moreover, these antibodies can be found in several other autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, and antiphospholipid syndrome (APS), more frequently than in control subjects.…”

The spectrum between antiphospholipid syndrome and systemic lupus erythematosus

“…Indeed, Arbuckle et al [13] found that 88 % of SLE patients were antibody positive up to 30 years prior to diagnosis and a stepwise accumulation of these antibodies was a marker of the preclinical stage of SLE. Similarly, the presence of anti-mitochondrial antibodies (AMA) in primary biliary cirrhosis (PBC), anti-Saccharomyces cerevisiae antibodies in Chron's disease, and anti-neutrophil cytoplasmic antibodies (ANCA) both in ulcerative colitis and in ANCA-associated vasculitis were documented years before diseases were overt [14][15][16]. Noteworthy, antiphospholipid antibodies presence may precede the diagnosis of APS in patients diagnosed both with primary or secondary APS.…”

Inflammatory bowel diseases: where we are and where we should go

“…In light of these considerations, it would seem advantageous to have multiplex tests (microarray, blot) using predefined profiles [7], in which diverse markers are tested simultaneously with the objective of providing a complete report, useful either for diagnostic orientation (Crohn's disease, ulcerative colitis or celiac disease) or for determining risk stratification. Multiple pathology-oriented antibody profiles might, in addition, demonstrate their usefulness in predicting IBD onset in the pre-diagnostic phase, as already demonstrated for ASCA [8], and very recently for anti-CBir1 and anti-OmpC [9] that have been detectable in the sera of apparently healthy subjects, on average 3-4 years before the disease became manifest, thus introducing a window of opportunity for early intervention.…”